JP2009515988A5 - - Google Patents
Info
- Publication number
- JP2009515988A5 JP2009515988A5 JP2008541330A JP2008541330A JP2009515988A5 JP 2009515988 A5 JP2009515988 A5 JP 2009515988A5 JP 2008541330 A JP2008541330 A JP 2008541330A JP 2008541330 A JP2008541330 A JP 2008541330A JP 2009515988 A5 JP2009515988 A5 JP 2009515988A5
- Authority
- JP
- Japan
- Prior art keywords
- saturated
- partially unsaturated
- alkyl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC=NN(*)C(*)=* Chemical compound CC=NN(*)C(*)=* 0.000 description 6
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73628905P | 2005-11-15 | 2005-11-15 | |
| US60/736,289 | 2005-11-15 | ||
| US81701906P | 2006-06-28 | 2006-06-28 | |
| US60/817,019 | 2006-06-28 | ||
| PCT/US2006/044431 WO2007059257A2 (en) | 2005-11-15 | 2006-11-15 | N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010198848A Division JP5232841B2 (ja) | 2005-11-15 | 2010-09-06 | Ｎ４−フェニルキナゾリン−４−アミン誘導体の製造方法およびその中間体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515988A JP2009515988A (ja) | 2009-04-16 |
| JP2009515988A5 true JP2009515988A5 (cg-RX-API-DMAC10.html) | 2010-10-21 |
| JP5134548B2 JP5134548B2 (ja) | 2013-01-30 |
Family
ID=38022019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541330A Active JP5134548B2 (ja) | 2005-11-15 | 2006-11-15 | 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物 |
| JP2010198848A Active JP5232841B2 (ja) | 2005-11-15 | 2010-09-06 | Ｎ４−フェニルキナゾリン−４−アミン誘導体の製造方法およびその中間体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010198848A Active JP5232841B2 (ja) | 2005-11-15 | 2010-09-06 | Ｎ４−フェニルキナゾリン−４−アミン誘導体の製造方法およびその中間体 |
Country Status (28)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| NZ545459A (en) | 2003-08-14 | 2009-12-24 | Array Biopharma Inc | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CN102887891B (zh) | 2005-11-15 | 2016-03-09 | 阿雷生物药品公司 | N4-苯基-喹唑啉-4-胺衍生物和相关化合物 |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| US8604044B2 (en) * | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| SG174772A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| CL2008001626A1 (es) * | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| CA2696948C (en) | 2007-09-14 | 2013-04-30 | Jose Maria Cid-Nunez | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| EP2200985B1 (en) | 2007-09-14 | 2011-07-13 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| NZ584148A (en) | 2007-09-14 | 2011-05-27 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| CN101861316B (zh) | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| CN102143955B (zh) | 2008-09-02 | 2013-08-14 | Omj制药公司 | 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物 |
| WO2010045095A1 (en) | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds and methods of use |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| EP2370428B1 (en) | 2008-12-11 | 2016-08-10 | Respivert Limited | P38 map kinase inhibitors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| ES2440001T3 (es) | 2009-05-12 | 2014-01-27 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| WO2011082271A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| ES2552879T3 (es) | 2010-11-08 | 2015-12-02 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| JP5918264B2 (ja) | 2010-12-22 | 2016-05-18 | アッヴィ・インコーポレイテッド | Ｃ型肝炎阻害剤およびその使用 |
| JP2014156400A (ja) * | 2011-05-24 | 2014-08-28 | Astellas Pharma Inc | 腫瘍の画像診断用標識誘導体 |
| KR20200003245A (ko) * | 2011-10-14 | 2020-01-08 | 어레이 바이오파마 인크. | 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물 |
| LT2765990T (lt) * | 2011-10-14 | 2018-01-25 | Array Biopharma, Inc. | Solidinė dispersija |
| RS57140B1 (sr) | 2012-03-23 | 2018-07-31 | Array Biopharma Inc | Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga |
| DK2964638T3 (en) * | 2013-03-06 | 2017-10-30 | Astrazeneca Ab | QUINAZOLIN INHIBITORS TO ACTIVATE MUTANEOUS FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR |
| KR102333718B1 (ko) * | 2013-03-15 | 2021-12-01 | 데시페라 파마슈티칼스, 엘엘씨. | 항암 및 항-증식 활성을 나타내는 n-아실-n'-(피리딘-2-일) 우레아 및 유사체 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| KR101974254B1 (ko) | 2013-07-18 | 2019-04-30 | 다이호야쿠힌고교 가부시키가이샤 | Fgfr 저해제의 간헐 투여용 항종양제 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| EA033889B1 (ru) | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа |
| LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| CN107531665B (zh) | 2014-12-15 | 2021-03-30 | 密歇根大学董事会 | Egfr和pi3k的小分子抑制剂 |
| KR101917557B1 (ko) | 2015-03-31 | 2018-11-09 | 다이호야쿠힌고교 가부시키가이샤 | 3,5-2치환 벤젠알키닐 화합물의 결정 |
| CN107141293B (zh) * | 2016-03-01 | 2022-09-23 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20250007056A (ko) | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| CN106117182B (zh) * | 2016-06-20 | 2019-08-30 | 中国药科大学 | 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| AU2017317864B2 (en) * | 2016-09-01 | 2020-01-16 | Transthera Sciences (Nanjing), Inc. | Inhibitors of fibroblast growth factor receptor and use thereof |
| US11525008B2 (en) | 2016-09-22 | 2022-12-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
| JP7053665B2 (ja) * | 2016-12-30 | 2022-04-12 | 南京明徳新薬研発有限公司 | Ｅｇｆｒ阻害としてのキナゾリン系化合物 |
| EA201992573A1 (ru) | 2017-04-28 | 2020-04-06 | Сиэтл Дженетикс, Инк. | Лечение her2-положительных злокачественных новообразований |
| CN109422755B (zh) * | 2017-09-01 | 2023-07-04 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| US20220411422A1 (en) * | 2018-05-08 | 2022-12-29 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Erbb receptor inhibitors |
| AR117424A1 (es) * | 2018-05-08 | 2021-08-04 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de los receptores erbb |
| CN112105618B (zh) * | 2018-05-08 | 2022-05-31 | 南京明德新药研发有限公司 | 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 |
| JP7546550B2 (ja) * | 2018-09-18 | 2024-09-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗腫瘍剤としてのキナゾリン誘導体 |
| CN109942576B (zh) * | 2019-03-07 | 2020-09-11 | 上海工程技术大学 | Irbinitinib及中间体的制备方法 |
| CN111825604A (zh) * | 2019-04-16 | 2020-10-27 | 宁波药腾医药科技有限公司 | 一种图卡替尼及其中间产物的合成方法 |
| WO2021088987A1 (zh) * | 2019-11-08 | 2021-05-14 | 南京明德新药研发有限公司 | 作为选择性her2抑制剂的盐型、晶型及其应用 |
| EP4100409B1 (en) | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| US20230131720A1 (en) * | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| AU2020435503B2 (en) * | 2020-03-13 | 2025-02-20 | F. Hoffmann-La Roche Ag | ErbB receptor inhibitors as anti-tumor agents |
| US11608343B2 (en) * | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) * | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| WO2022140769A1 (en) * | 2020-12-22 | 2022-06-30 | Enliven Therapeutics, Inc. | Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2 |
| EP4267554A1 (en) | 2020-12-22 | 2023-11-01 | Mekanistic Therapeutics LLC | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| MX2023012060A (es) * | 2021-04-13 | 2024-01-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr. |
| CR20230604A (es) * | 2021-06-26 | 2024-02-19 | Array Biopharma Inc | Inhibidores de mutación de her2 |
| KR102598580B1 (ko) * | 2021-07-16 | 2023-11-06 | 한양대학교 에리카산학협력단 | 니트로알켄 화합물의 신규 제조방법 |
| PE20242106A1 (es) * | 2021-10-20 | 2024-10-28 | Hoffmann La Roche | Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas |
| WO2023081637A1 (en) | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| KR102884401B1 (ko) * | 2022-02-25 | 2025-11-11 | 중앙대학교 산학협력단 | 헤테로아릴 유도체를 유효성분으로 함유하는 her2 억제용 조성물 |
| CA3253847A1 (en) * | 2022-03-28 | 2025-07-04 | Shanghai Hengrui Pharmaceutical Co., Ltd. | HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE |
| AU2023250757A1 (en) * | 2022-04-05 | 2024-03-21 | Voronoi Inc. | Heteroaryl derivative and use thereof |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2024027695A1 (zh) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | 作为her2抑制剂的化合物 |
| CN115650975B (zh) * | 2022-08-23 | 2024-07-02 | 四川大学华西医院 | 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用 |
| WO2025034912A2 (en) | 2023-08-07 | 2025-02-13 | Cogent Biosciences, Inc. | Compounds for fgfr inhibition |
| WO2025067396A1 (zh) * | 2023-09-27 | 2025-04-03 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的可药用盐、其结晶形式及用途 |
| WO2025067398A1 (zh) * | 2023-09-27 | 2025-04-03 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的结晶形式及其制备方法 |
| CN118084901A (zh) * | 2023-12-15 | 2024-05-28 | 江苏希迪制药有限公司 | 妥卡替尼的合成方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| DE2653005A1 (de) * | 1975-12-03 | 1977-06-08 | Sandoz Ag | Neue organische verbindungen, ihre verwendung und herstellung |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| US5204348A (en) | 1988-10-06 | 1993-04-20 | Mitsui Toatsu Chemicals Inc. | Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5517680A (en) | 1992-01-22 | 1996-05-14 | Ericsson Inc. | Self correction of PST simulcast system timing |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (cg-RX-API-DMAC10.html) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| GEP20012442B (en) | 1996-04-12 | 2001-05-25 | Warner Lambert Co | Irreversible Inhibitors of Tyrosine Kinases |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| DE19735682A1 (de) | 1997-08-19 | 1999-02-25 | Basf Ag | Verfahren zur Herstellung von 3-Isopropyl-1H-2,1,3-benzothiadiazin-4(3H)-on-2,2-dioxid |
| HUP0100287A3 (en) | 1997-11-11 | 2003-04-28 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| JP2002505288A (ja) | 1998-03-02 | 2002-02-19 | コセンシス，インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
| US6017922A (en) | 1998-05-18 | 2000-01-25 | U.S. Bioscience, Inc. | Thermally stable trimetrexates and processes for producing the same |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| HK1041697A1 (zh) | 1999-01-13 | 2002-07-19 | 沃尼尔‧朗伯公司 | 苯并杂环和它们作为mek抑制剂的用途 |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| US7081461B1 (en) | 1999-09-21 | 2006-07-25 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| ES2223827T3 (es) | 2000-06-06 | 2005-03-01 | Pfizer Products Inc. | Derivados de tiofeno utiles como agentes anticancerigenos. |
| WO2001098277A2 (en) | 2000-06-22 | 2001-12-27 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| NZ522989A (en) | 2000-06-30 | 2005-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
| JP2004517059A (ja) | 2000-11-02 | 2004-06-10 | アストラゼネカ アクチボラグ | 抗腫瘍剤用の４−置換キノリン類 |
| SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| AU2002338286A1 (en) | 2001-04-10 | 2002-10-28 | Leo Pharma A/S | Novel aminophenyl ketone derivatives |
| GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| ATE423104T1 (de) | 2001-11-03 | 2009-03-15 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
| US6756006B1 (en) | 2002-03-05 | 2004-06-29 | Peter Levijoki | Method of forming sculptured designs onto a substrate |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| CA2514479A1 (en) | 2003-01-23 | 2004-08-05 | T.K. Signal Ltd. | Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof |
| PE20040945A1 (es) | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1636195A1 (en) | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
| WO2005007083A2 (en) | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| NZ545459A (en) | 2003-08-14 | 2009-12-24 | Array Biopharma Inc | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| MXPA06001989A (es) | 2003-08-18 | 2006-05-17 | Pfizer Prod Inc | Programa de dosificacion para un nuevo agente anticanceroso. |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| GB0321648D0 (en) | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| JP2007505873A (ja) | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| MXPA06005024A (es) | 2003-11-06 | 2006-07-06 | Pfizer Prod Inc | Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer. |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| CN102887891B (zh) * | 2005-11-15 | 2016-03-09 | 阿雷生物药品公司 | N4-苯基-喹唑啉-4-胺衍生物和相关化合物 |
-
2006
- 2006-11-15 CN CN201210320423.2A patent/CN102887891B/zh active Active
- 2006-11-15 AT AT06837728T patent/ATE446294T1/de active
- 2006-11-15 PL PL09157031T patent/PL2090575T3/pl unknown
- 2006-11-15 RU RU2008118417/04A patent/RU2428421C2/ru active
- 2006-11-15 SI SI200631044T patent/SI2090575T1/sl unknown
- 2006-11-15 BR BRPI0618668-8A patent/BRPI0618668B1/pt active IP Right Grant
- 2006-11-15 EP EP06837728A patent/EP1971601B1/en active Active
- 2006-11-15 CA CA2632194A patent/CA2632194C/en active Active
- 2006-11-15 CN CNA2006800506892A patent/CN101356171A/zh active Pending
- 2006-11-15 KR KR1020087014416A patent/KR101086967B1/ko active Active
- 2006-11-15 ES ES09157031T patent/ES2364901T3/es active Active
- 2006-11-15 ES ES06837728T patent/ES2335535T3/es active Active
- 2006-11-15 SG SG200902466-2A patent/SG152230A1/en unknown
- 2006-11-15 DE DE602006021645T patent/DE602006021645D1/de active Active
- 2006-11-15 DK DK06837728.2T patent/DK1971601T3/da active
- 2006-11-15 DK DK09157031.7T patent/DK2090575T3/da active
- 2006-11-15 ZA ZA200804498A patent/ZA200804498B/xx unknown
- 2006-11-15 DE DE602006009968T patent/DE602006009968D1/de active Active
- 2006-11-15 AU AU2006315383A patent/AU2006315383B2/en active Active
- 2006-11-15 PL PL06837728T patent/PL1971601T3/pl unknown
- 2006-11-15 PT PT09157031T patent/PT2090575E/pt unknown
- 2006-11-15 US US12/085,048 patent/US8648087B2/en active Active
- 2006-11-15 EP EP09157031A patent/EP2090575B1/en active Active
- 2006-11-15 CA CA2755268A patent/CA2755268C/en active Active
- 2006-11-15 PT PT06837728T patent/PT1971601E/pt unknown
- 2006-11-15 WO PCT/US2006/044431 patent/WO2007059257A2/en not_active Ceased
- 2006-11-15 JP JP2008541330A patent/JP5134548B2/ja active Active
- 2006-11-15 AT AT09157031T patent/ATE507224T1/de active
- 2006-11-15 SI SI200630539T patent/SI1971601T1/sl unknown
- 2006-11-15 BR BR122018075851-1A patent/BR122018075851B1/pt active IP Right Grant
- 2006-11-15 RU RU2011122539/04A patent/RU2592703C9/ru active
-
2008
- 2008-06-10 NO NO20082598A patent/NO342413B1/no unknown
-
2010
- 2010-01-15 CY CY20101100043T patent/CY1110583T1/el unknown
- 2010-06-04 AU AU2010202330A patent/AU2010202330B2/en active Active
- 2010-09-06 JP JP2010198848A patent/JP5232841B2/ja active Active
-
2011
- 2011-07-15 CY CY20111100696T patent/CY1112754T1/el unknown
-
2013
- 2013-09-23 US US14/034,361 patent/US9693989B2/en active Active
-
2015
- 2015-06-02 IL IL239149A patent/IL239149A/en active IP Right Grant
-
2016
- 2016-11-15 IL IL248993A patent/IL248993B/en active IP Right Grant
-
2017
- 2017-05-19 US US15/599,867 patent/US20170252317A1/en not_active Abandoned
-
2018
- 2018-05-09 US US15/975,323 patent/US10780073B2/en active Active
-
2020
- 2020-07-27 US US16/940,091 patent/US20210008023A1/en not_active Abandoned
-
2021
- 2021-07-06 NL NL301113C patent/NL301113I2/nl unknown
- 2021-07-09 FI FIC20210022C patent/FIC20210022I1/fi unknown
- 2021-07-09 CY CY2021019C patent/CY2021019I2/el unknown
- 2021-07-20 LU LU00217C patent/LUC00217I2/fr unknown
- 2021-07-20 FR FR21C1031C patent/FR21C1031I2/fr active Active
- 2021-07-20 LT LTPA2021516C patent/LTC1971601I2/lt unknown
- 2021-07-29 HU HUS2100028C patent/HUS2100028I1/hu unknown
-
2022
- 2022-09-08 US US17/940,902 patent/US12171739B2/en active Active